By David Tuller, DrPH I have been trying to convince editors at two BMJ journals to take responsibility for poor decisions. Despite serious nudging and prodding, I have been unsuccessful. The two papers I have criticized as being fraught with methodological and/or ethical missteps are these: Clinical and cost-effectiveness of ...

By David Tuller, DrPH Two weeks ago I sent an e-mail to Sir Andrew Dillon and Professor Mark Baker alerting them of problems with the Lightning Process study published last year in Archives of Disease in Childhood. The two men are members of the NICE Guidance Executive and have a ...

By David Tuller, DrPH When the PACE trial was published in early 2011, my New York Times editor sent it to me, along with the press release. As a non-staff contributor to the Times, I had started covering the debate over the mouse retrovirus hypothesis and science, but I'd heard ...

By David Tuller, DrPH Earlier this month, in advance of a stakeholder meeting, the U.K.'s National Institute for Health and Care Excellence released a draft scoping report. The document outlined the issues slated to be addressed by the committee selected to develop the new guidance for the illness NICE now ...

By David Tuller, DrPH It’s been almost a year since the CDC removed its recommendations for GET and CBT as treatments for ME/CFS (or CFS, or ME, or CFS/ME, or even SEID or whatever else one calls this illness or cluster of illnesses). When questioned about the decision, the agency ...